# Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease

> **NCT00072839** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 100 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** ALX-0600
- **DRUG:** placebo
- **DRUG:** teduglutide 0.05
- **DRUG:** teduglutide 0.2 mg
- **DRUG:** Teduglutide 0.05 dose
- **DRUG:** teduglutide 0.1 mg dose

## Key facts

- **NCT ID:** NCT00072839
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11-12
- **Primary completion:** 2005-07-28
- **Final completion:** 2005-07-28
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072839, "Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00072839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*